VivoSeq
Oncology

Prolymphocytic Leukemia

6

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Prolymphocytic Leukemia is an early-stage landscape with 6 programs across 3 companies. The most active players are Roche, Sanofi, Genzyme, a Sanofi Company. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

50/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2G

Genzyme, a Sanofi Company

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

7programs
Small molecule457%
Monoclonal antibody343%

Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

4

clinical trials

Completed1 · 25%
Terminated1 · 25%
Recruiting1 · 25%
Active, not recruiting1 · 25%

Clinical Trials

Trial Activity

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)
Completed·GGerman CLL Study Group·Phase 2·NCT01186640·16 enrolled
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia
Terminated·GGerman CLL Study Group·Phase 2·NCT00281931·21 enrolled
Prospective and Retrospective Study Evaluating Epidemiological, Clinical, Molecular and Therapeutic Data of Prolymphocytic Leukemia T. A FILO Study.
Recruiting·FFrench Innovative Leukemia Organisation·N/A·NCT04411043·50 enrolled
Ibrutinib vs Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed (CLL)
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02007044·66 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)